Kura Oncology’s CEO, Troy Wilson, to Speak at Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2025 – Kura Oncology, a pioneering biopharmaceutical company dedicated to the development of precision medicines for cancer treatment, announced today that its President and CEO, Troy Wilson, Ph.D., J.D., will attend and participate in three upcoming investor conferences.
Conferences and Dates
The first conference will be the 30th Annual J.P. Morgan Healthcare Conference held in San Francisco, California, from January 9 to 13, 2026. Dr. Wilson is scheduled to present an update on Kura Oncology’s business and development pipeline on Monday, January 10, 2026.
Next, he will participate in the Cowen 41st Annual Health Care Conference in Boston, Massachusetts, on February 5-8, 2026. Although no specific presentation time was given, attendees can meet with Dr. Wilson and other Kura Oncology representatives during the event.
Lastly, Dr. Wilson will speak at the B. Riley Securities 12th Annual Institutional Investor Conference on Consumer, Retail & Restaurant Companies in Miami, Florida, on March 8-9, 2026. He is scheduled to present on Wednesday, March 9, 2026.
Impact on Individuals
For those interested in Kura Oncology’s progress and potential impact on cancer treatment, these investor conferences offer an excellent opportunity to gain insights into the company’s latest research, clinical trials, and business strategies. Dr. Wilson’s presentations and interactions with investors may shed light on the potential value of Kura Oncology’s precision medicines and their role in the future of cancer treatment.
Impact on the World
These investor conferences can have far-reaching implications for the world of oncology and the biopharmaceutical industry as a whole. Kura Oncology’s participation in these events can help raise awareness of the importance of precision medicines in cancer treatment and potentially attract new investors and partnerships, furthering the company’s mission to bring innovative treatments to patients.
Conclusion
In summary, Kura Oncology’s CEO, Troy Wilson, will be presenting at three major investor conferences in the coming months. These events offer valuable opportunities for individuals to learn about the company’s progress and potential impact on cancer treatment. Furthermore, Kura Oncology’s participation can help advance the field of precision oncology and attract new investors and collaborations, ultimately benefiting patients and the scientific community.
- Kura Oncology’s CEO, Troy Wilson, to present at J.P. Morgan Healthcare Conference, Cowen 41st Annual Health Care Conference, and B. Riley Securities 12th Annual Institutional Investor Conference on Consumer, Retail & Restaurant Companies.
- Individuals can gain insights into Kura Oncology’s latest research, clinical trials, and business strategies.
- Kura Oncology’s participation can help raise awareness of precision medicines and potentially attract new investors and partnerships.
